Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.

Monk, Bradley J;Romero, Ignacio;Graybill, Whitney;Churruca, Cristina;González-Martín, Antonio;et.al.
(2024) Clinical Therapeutics : the international peer-reviewed journal of drug therapy — Vol. 46, n° 8, p. 612-621 (2024)

Files

2024_Monk_Clin_Ther.pdf
  • Open Access
  • Adobe PDF
  • 969.19 KB
  • https://creativecommons.org/licenses/by/4.0/
Download

Details

Authors
  • Monk, Bradley J
    Author
  • Romero, Ignacio
    Author
  • Graybill, Whitney
    Author
  • Churruca, Cristina
    Author
  • Baurain, Jean-Françoisorcid-logoUCLouvain
    Author
  • González-Martín, Antonio
    Author
Show more
Abstract
PURPOSE: Niraparib is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor approved for the maintenance treatment of advanced ovarian cancer (OC). Niraparib was originally approved in recurrent OC at a fixed starting dose (FSD) of 300 mg once daily (QD). This analysis characterized the population pharmacokinetics (PK) of niraparib and evaluated the relationships between exposure, efficacy, and safety to support clinical use of an individualized dosing strategy, in which the starting dose of niraparib was adjusted based on patient characteristics to improve the benefit-risk profile. METHODS: A population PK model was developed by pooling data from four niraparib clinical trials (PN001 [n = 104], QUADRA [n = 455], NOVA [n = 403], and PRIMA [n = 480]) in patients with solid tumors, including OC. Exposure-response analyses were conducted to explore the relationships of niraparib exposure with progression-free survival (PFS) and adverse events in the PRIMA study. A multivariate logistic regression model was also developed to estimate the probability of grade ≥3 thrombocytopenia, using data from patients enrolled in PRIMA and NOVA. The impact of an individualized starting dose (ISD) regimen (200 mg QD in patients with body weight [BW] <77 kg or platelet count [PLT] <150,000/µL, or 300 mg QD in patients with BW ≥77 kg and PLT ≥150,000/µL) on systemic exposure, efficacy, and safety was assessed. FINDINGS: Niraparib disposition was best described by a 3-compartment model with linear elimination. Key covariates included baseline creatinine clearance, BW, albumin, and age, all of which had minor effects on niraparib exposure. Comparable model-predicted exposure up to the time of disease progression/death or censoring in the 300-mg FSD and 200-/300-mg ISD groups was consistent with the lower rate of dose reduction in the ISD groups. No consistent niraparib exposure-response relationship was observed for efficacy in all PRIMA patients (first-line OC), and no statistically significant difference was seen in PFS curves for patients receiving a niraparib dose of 200 mg versus 300 mg. In the multivariate regression model, performed using combined data from PRIMA and NOVA, higher niraparib exposure (area under the concentration-time curve at steady-state [AUCss]), lower BW, and lower PLT were associated with an increased risk of grade ≥3 thrombocytopenia. IMPLICATIONS: Population PK and exposure-response analyses support use of an ISD to improve the safety profile of niraparib, including reducing the rate of grade ≥3 thrombocytopenia, without compromising efficacy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01847274 (NOVA), NCT00749502 (PN001), NCT02655016 (PRIMA), NCT02354586 (QUADRA), www.clinicaltrials.gov.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Monk, B. J., Romero, I., Graybill, W., Churruca, C., O’Malley, D. M., Knudsen, A. Ø., Yap, O. W. S., Baurain, J.-F., Rose, P. G., Denys, H., Ghamande, S., Pisano, C., Fabbro, M., Braicu, E. I., Calvert, P. M., Amit, A., Prendergast, E., Taylor, A., Kheibarshekan, L., et al. (2024). Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer. Clinical Therapeutics : the international peer-reviewed journal of drug therapy, 46(8), 612-621. https://doi.org/10.1016/j.clinthera.2024.06.001 (Original work published 2024)